胆管癌靶向新药培米替尼(PEMIGATINIB)的临床研究结果

The U.S. Food and Drug Administration (FDA) approved lncyte's latest targeted drug (pemigatimib, CAS registration number 1513857-77-6) through accelerated approval on April 17, 2020, for the treatment of adults with advanced FCFR2 gene fusion cholangiocarcinoma (Cholangiocarcinoma) that has been previously treated but failed to respond.

Cholangiocarcinoma is a malignant tumor originating from the bile duct epithelium. Although its incidence is low, cholangiocarcinoma is the second most common primary malignant tumor of the liver after liver cancer. Overall, approximately 5% to 10% are located within the liver, 60% to 70% are located around the liver portal, and 20% to 30% are located outside the liver. In hilar cholangiocarcinoma, only 20% to 30% of patients can undergo radical surgical resection, and most patients can only receive palliative treatment.

Pemetinib, as a protein kinase inhibitor, exerts a strong and selective inhibitory effect on FGFR subtypes 1/2/3. The effective rate of second-line treatment of cholangiocarcinoma is 35.5%, and the control rate is 82%. They include: dry eyes, dry mouth, decreased appetite, hyper/hypophosphatemia (electrolyte imbalance), alopecia, diarrhea, vomiting, joint pain, eye toxicity, nail toxicity, fatigue, indigestion (taste distortion), nausea, abdominal pain, constipation, stomatitis, back pain, dry skin, etc.

Finally, the editor of Medical Companion Travel would like to remind patients who are currently using pemetinib that there has been a lot of loose news recently saying that if the patient feels that the drug is not effective after using it, the drug dose can be increased, or that the drug dose can be reduced if the side effects are too great during the medication. These are not scientifically based. Only by carefully following the doctor's instructions can the drug itself be used to its greatest extent.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.